ChinaBio Today submits: GlaxoSmithKline (GSK) has made a strategic alliance with Aspen PharmaCare, a South African generic drug company, as a means of penetrating emerging markets such as China. GSK noted that 40% of the expected growth in pharmaceutical markets worldwide will be in emerging countries. The new strategy for GSK is a dramatic change from its traditional reliance on high-cost patented drugs. Instead, Glaxo is turning toward vaccines, OTC medications, consumer healthcare and, now, branded generic drugs. The blockbuster model that has traditionally been the basis for big pharma’s profits has fallen apart as the blockbuster drugs have lost their patent protection. Big pharma has been unable to develop new billion dollar medications to replace them. Complete Story » ...
Anytime
ChinaBio Today submits: GlaxoSmithKline (GSK) has made a strategic alliance with Aspen PharmaCare, a South African generic drug company, as a means of penetrating emerging markets such as China. GSK noted that 40% of the expected growth in pharmaceutical markets worldwide will be in emerging countries. The new strategy for GSK is a dramatic change from its traditional reliance on high-cost patented drugs. Instead, Glaxo is turning toward vaccines, OTC medications, consumer healthcare and, now, branded generic drugs. The blockbuster model that has traditionally been the basis for big pharma’s profits has fallen apart as the blockbuster drugs have lost their patent protection. Big pharma has been unable to develop new billion dollar medications to replace them. Complete Story » ...